Medscape is available in 5 Language Editions – Choose your Edition here.


Alcoholic Hepatitis Workup

  • Author: Douglas M Heuman, MD, FACP, FACG, AGAF; Chief Editor: BS Anand, MD  more...
Updated: Dec 27, 2015

Approach Considerations

The diagnosis of alcoholic hepatitis is straightforward and requires no further diagnostic studies in patients presenting with a history of alcohol abuse, typical symptoms and physical findings, evidence of liver functional impairment, and compatible liver enzyme levels. In milder cases of alcoholic hepatitis, a mild elevation of the aspartate aminotransferase (AST) level may be the only diagnostic clue.

Studies have indicated that serum C-reactive protein (CRP) is an accurate marker of alcoholic hepatitis (ie, sensitivity, 41%; specificity, 99%; positive predictive value [PPV], 98%; negative predictive value [NPV], 88%).[17]

An electrolyte panel may demonstrate electrolyte disorders from the effects of vomiting, portal hypertension with decreased circulating volume, alcoholic ketoacidosis, or respiratory alkalosis. In addition, hypophosphatemia and hypomagnesemia are common consequences of coexistent malnutrition.

In August 2012, the Centers for Disease Control and Prevention (CDC) expanded their existing, risk-based testing guidelines to recommend a 1-time blood test for hepatitis C virus (HCV) infection in baby boomers—the generation born between 1945 and 1965, who account for approximately three fourths of all chronic HCV infections in the United States—without prior ascertainment of HCV risk (see Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965).[16] One-time HCV testing in this population could identify nearly 808,600 additional people with chronic infection. All individuals identified with HCV should be screened and/or managed for alcohol abuse, followed by referral to preventative and/or treatment services, as appropriate.

Imaging studies are rarely required for the diagnosis of alcoholic hepatitis, but they can be useful in excluding other causes of liver disease. Ultrasonography is generally the preferred modality due to its low cost, noninvasiveness, and wide availability. Similar and complementary information can be obtained by computed tomography (CT) scanning or magnetic resonance imaging (MRI) of the abdomen; however, these 2 imaging studies are more expensive than ultrasonography and are usually required only in atypical cases. CT scanning and MRI are more sensitive and accurate than ultrasonography if cancer is suspected.


CBC Count

A complete blood cell (CBC) count commonly reveals some degree of neutrophilic leukocytosis with bandemia. Usually, this is moderate; however, rarely, it is severe enough to provide a leukemoid picture.

Alcohol is a direct marrow suppressant, and moderate anemia may be observed. In addition, alcohol use characteristically produces a moderate increase in mean corpuscular volume.

Thrombocytosis may be observed as part of the inflammatory response; conversely, myelosuppression or portal hypertension with splenic sequestration may produce thrombocytopenia.


Screening Blood Tests

Screening blood tests to exclude other conditions (appropriate in any patient with alcoholic hepatitis) may include the following:

  • Hepatitis B surface antigen (HBsAg) detects hepatitis B
  • Anti–hepatitis C virus by enzyme-linked immunosorbent assay (ELISA) detects hepatitis C
  • Ferritin and transferrin saturation detect hemochromatosis
  • Marked elevation of aminotransferase levels should raise concern for viral hepatitis or drug hepatotoxicity; in particular, people who are alcoholics may develop severe liver necrosis from standard therapeutic doses of acetaminophen
  • Rapid deterioration of liver function (see Liver Tests) should raise the possibility of hepatocellular carcinoma (HCC), which can be tested for by determination of alpha-fetoprotein (AFP) levels
  • Jaundice with fever can be caused by gallstones producing cholangitis and is suggested by a disproportionate elevation of the alkaline phosphatase (ALP) level

Liver Tests

Liver enzyme levels exhibit a characteristic pattern. In most patients, the aspartate aminotransferase (AST) level is moderately elevated, whereas the alanine aminotransferase (ALT) level is in the reference range or only mildly elevated. This is the opposite of what is observed in most other liver diseases.

An AST/ALT ratio greater than 1 is almost universal in persons with alcoholic hepatitis. Even in severe disease, the elevations of aminotransferase levels are modest, and an AST level greater than 500 U/L should raise suspicion of an alternative diagnosis. An AST/ALT ratio greater than 1 may accompany cirrhosis of any cause and, therefore, is less diagnostically specific in the setting of cirrhosis.

Alkaline phosphatase (ALP) level elevations are typically mild in persons with alcoholic hepatitis. Levels greater than 500 U/L occur in a small percentage of patients, but abnormalities of this magnitude suggest a coexisting infiltrative or biliary obstructive process.

The gamma-glutamyl transpeptidase (GGTP) level is elevated markedly by alcohol use. Although a normal value helps to exclude alcohol as a cause of liver disease, an elevated level is of no value in distinguishing between simple alcoholism and alcoholic hepatitis.

Liver function tests

Common liver function tests include albumin level, bilirubin level, and prothrombin time (PT). Hypoalbuminemia occurs because of decreased hepatic synthetic function and coexisting protein-energy malnutrition (PEM). Hyperbilirubinemia is typically a mixture of unconjugated and conjugated bilirubin, with the latter predominating. Bilirubinuria is normally present in patients who are icteric. Coagulopathy predominantly affects the extrinsic pathway of coagulation (measured by PT). It is usually unresponsive to vitamin K.

The severity of hyperbilirubinemia and coagulopathy reflects the severity of alcoholic hepatitis and is of prognostic value.

Serum biomarkers

Ash test

The diagnostic value of serum biomarkers, such as the Ash test (ie, the 6 components of the FibroTest-ActiTest plus AST), was tested and validated in 275 patients with alcoholic hepatitis.[18] Both the sensitivity and the specificity of the Ash test in predicting alcoholic steatohepatitis were impressive (0.80 and 0.84, respectively).[18]

Carbohydrate-deficient transferrin (CDT)

Carbohydrate-deficient transferrin is perhaps the most reliable marker of chronic alcoholism, irrespective of the presence of liver disease.[19] Carbohydrate-deficient transferrin has been proposed as a reliable biomarker in the differentiation of nonalcoholic steatohepatitis (NASH) from alcoholic hepatitis.[20]



In general, real-time ultrasonography is the preferred imaging study in evaluating patients with suspected alcoholic hepatitis, because it is inexpensive, noninvasive, and widely available. This modality provides a good evaluation of the liver and other viscera, and it permits guided liver biopsy.

On ultrasonograms, the liver in patients with alcoholic hepatitis appears enlarged and diffusely hyperechoic. Features suggestive of coexistent portal hypertension and/or cirrhosis include the presence of varices, splenomegaly, and ascites.

Ultrasonography is also helpful in excluding gallstones, bile duct obstruction, and hepatic or biliary neoplasms. Jaundice with fever can be caused by gallstones producing cholangitis; ultrasonographic examination of the abdomen is usually sufficient to exclude this possibility. However, if stones are found or fever persists, cholangiography may be necessary.

Rapid deterioration of liver function should raise the possibility of hepatocellular carcinoma, which can be tested for by performing imaging studies (eg, ultrasonography, computed tomography [CT] scanning, magnetic resonance imaging [MRI]) of the liver.


Liver Biopsy

Liver biopsy is not always required in the evaluation of alcoholic hepatitis, but it may be useful in establishing the diagnosis, in determining the presence or absence of cirrhosis, and in excluding other causes of liver disease.

The 2010 American Association for the Study of Liver Diseases (AASLD) alcoholic liver disease (ALD) practice guideline recommends considering liver biopsy for patients whose diagnosis is reasonably uncertain and for patients likely to undergo medical treatment for severe alcoholic hepatitis. The risk of performing the biopsy should be weighed against the risk associated with the probable course of therapy, or the possible risk of an investigational treatment.[3]

Percutaneous liver biopsy

Percutaneous biopsy can be performed at the bedside by an experienced practitioner, usually a gastroenterologist or a hepatologist. Real-time ultrasonographic guidance may be desirable to optimize biopsy site selection and to reduce the risk of complications.

Usually, a biopsy should be avoided in the presence of severe thrombocytopenia or coagulopathy because of the risk of serious (possibly fatal) hemorrhage.

Transjugular liver biopsy

If biopsy information is considered essential and the risk of percutaneous biopsy appears excessive, an alternative approach is to perform a biopsy angiographically via a catheter passed into the hepatic vein under fluoroscopic guidance. In principle, the risk of hemorrhage should be reduced, because the puncture site is contained within the venous system.

At the time of transjugular liver biopsy, the angiographer can determine the transhepatic venous pressure gradient. In alcoholic hepatitis and cirrhosis, the pressure measurement obtained with a catheter wedged retrograde in a branch of the hepatic vein accurately reflects the portal venous pressure.


Histologic Features

In alcoholic hepatitis, liver injury is characteristically most prominent in the centrilobular (perivenular) areas (zone 3 of Rappaport). Hepatocytes exhibit ballooning with necrosis. Focal accumulation of polymorphonuclear leukocytes, as shown in the image below, is noted in the areas of injury. Lymphocytes may also be present, especially in the portal tracts.

Liver biopsy sample shows typical findings of peri Liver biopsy sample shows typical findings of perivenular polymorphonuclear infiltrate and ballooning degeneration of hepatocytes (hematoxylin and eosin [H&E] stain). Courtesy of H. Robert Lippman, MD.

Ropy eosinophilic hyaline inclusions termed Mallory bodies may be observed in the perinuclear cytoplasm. With electron microscopy, Mallory bodies may be observed to be composed of fibril clumps that histochemically are identifiable as intermediate filaments. Mallory bodies are characteristic of alcoholic hepatitis, but they are not always present in this disease, and, occasionally, they can be observed in a variety of other disorders.

Macrovesicular steatosis, perivenular fibrosis, and frank cirrhosis commonly coexist with alcoholic hepatitis.

Contributor Information and Disclosures

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of Hepatology, Hunter Holmes McGuire Department of Veterans Affairs Medical Center; Professor, Department of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, American Gastroenterological Association

Disclosure: Received grant/research funds from Novartis for other; Received grant/research funds from Bayer for other; Received grant/research funds from Otsuka for none; Received grant/research funds from Bristol Myers Squibb for other; Received none from Scynexis for none; Received grant/research funds from Salix for other; Received grant/research funds from MannKind for other.


Patrick D Hung, MD Senior Fellow, Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine

Disclosure: Nothing to disclose.

Anastasios A Mihas, MD, DMSc, FACP, FACG Professor, Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine; Consulting Staff, Virginia Commonwealth University Hospitals and Clinics; Chief of GI Clinical Research, Director of GI Outpatient Service, Associate Director of Hepatology, Hunter Holmes McGuire Veterans Affairs Medical Center

Anastasios A Mihas, MD, DMSc, FACP, FACG is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Sigma Xi, Southern Society for Clinical Investigation, American Federation for Clinical Research, Gastroenterology Research Group

Disclosure: Nothing to disclose.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.


Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

George Y Wu, MD, PhD Professor, Department of Medicine, Director, Hepatology Section, Herman Lopata Chair in Hepatitis Research, University of Connecticut School of Medicine

George Y Wu, MD, PhD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, American Medical Association, American Society for Clinical Investigation, and Association of American Physicians

Disclosure: Springer Consulting fee Consulting; Gilead Consulting fee Review panel membership; Gilead Honoraria Speaking and teaching; Bristol-Myers Squibb Honoraria Speaking and teaching; Springer Royalty Review panel membership

  1. Casanova J, Bataller R. Alcoholic hepatitis: Prognosis and treatment. Gastroenterol Hepatol. 2014 Apr. 37 (4):262-8. [Medline].

  2. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009 Jul 28. 15(28):3462-71. [Medline]. [Full Text].

  3. [Guideline] O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010 Jan. 51(1):307-28. [Medline]. [Full Text].

  4. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease?. Hepatology. 2006 Feb. 43(2):352-61. [Medline].

  5. Lieber CS, DeCarli LM. An experimental model of alcohol feeding and liver injury in the baboon. J Med Primatol. 1974. 3(3):153-63. [Medline].

  6. Testino G, Sumberaz A, Ancarani AO, Borro P, Ravetti G, Ansaldi F, et al. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis. Hepatogastroenterology. 2009 Mar-Apr. 56(90):501-3. [Medline].

  7. Shoreibah M, Anand BS, Singal AK. Alcoholic hepatitis and concomitant hepatitis C virus infection. World J Gastroenterol. 2014 Sep 14. 20(34):11929-34. [Medline]. [Full Text].

  8. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995 Sep. 22(3):767-73. [Medline].

  9. Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013 Sep. 38(6):584-95. [Medline].

  10. Horie Y, Ishii H, Hibi T. Severe alcoholic hepatitis in Japan: prognosis and therapy. Alcohol Clin Exp Res. 2005 Dec. 29(12 Suppl):251S-8S. [Medline].

  11. Mihas AA, Doos WG, Spenney JG. Alcoholic hepatitis--a clinical and pathological study of 142 cases. J Chronic Dis. 1978. 31(6-7):461-72. [Medline].

  12. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005 Feb. 41(2):353-8. [Medline].

  13. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol. 2005 May. 42:700-6. [Medline].

  14. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glascow alcoholic hepatitis score. Gut. 2005 Aug. 54:14-5. [Medline].

  15. Mookerjee RP, Malaki M, Davies NA, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology. 2007 Jan. 45:62-71. [Medline].

  16. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012 Aug 17. 61:1-32. [Medline]. [Full Text].

  17. Vanbiervliet G, Le Breton F, Rosenthal-Allieri MA, Gelsi E, Marine-Barjoan E, Anty R, et al. serum C-reactive protein: A non-invasive marker of alcoholic hepatitis. Scand J Gastroenterol. 2006 Dec. 41:1473-9. [Medline].

  18. Thabut D, Naveau S, Charlotte F, et al. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol. 2006 Jun. 44:1175-85. [Medline].

  19. Mihas AA and Tavassoli M. Laboratory markers of ethanol intake and abuse: a critical appraisal. Am J Med Sci. 1992 Jun. 303:415-28. [Medline].

  20. Ohtsuka T, Tsutsumi M, Fukumura A, Tsuchishima M, Takase S. Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. Alcohol Clin Exp Res. Dec 2005. 29(12 suppl):236S-9S. [Medline].

  21. Colmenero J, Bataller R, Sancho-Bru P, et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology. 2007 Feb. 132:687-97. [Medline].

  22. Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res. 1995 Jun. 19(3):635-41. [Medline].

  23. Lucey MR. Management of alcoholic liver disease. Clin Liver Dis. 2009 May. 13(2):267-75. [Medline].

  24. Osterwell N. STOPAH: Only Steroid Reduces Alcoholic Hepatitis Death Risk. Available at Accessed: November 14, 2014.

  25. Thursz M, Forrest E, Roderick P, et al. The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. Health Technol Assess. 2015 Dec. 19 (102):1-104. [Medline].

  26. Immordino G, Gelli M, Ferrante R, et al. Alcohol abstinence and orthotopic liver transplantation in alcoholic liver cirrhosis. Transplant Proc. 2009 May. 41(4):1253-5. [Medline].

  27. Pfitzmann R, Schwenzer J, Rayes N, Seehofer D, Neuhaus R, Nussler NC. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007 Feb. 13(2):197-205. [Medline].

  28. Lucey MR, Schaubel DE, Guidinger MK, Tome S, Merion RM. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology. 2009 Aug. 50(2):400-6. [Medline].

  29. Webb K, Shepherd L, Day E, Masterton G, Neuberger J. Transplantation for alcoholic liver disease: report of a consensus meeting. Liver Transpl. 2006 Feb. 12(2):301-5. [Medline].

  30. Lucey MR. Liver transplantation for alcoholic liver disease: past, present, and future. Liver Transpl. 2007 Feb. 13(2):190-2. [Medline].

  31. McCormick PA, Burroughs AK. Relation between liver pathology and prognosis in patients with portal hypertension. World J Surg. 1994 Mar-Apr. 18(2):171-5. [Medline].

  32. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013 Sep 11. 310(10):1033-41. [Medline].

  33. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002 Oct. 37(4):448-55. [Medline].

  34. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003 Apr. 38(4):419-25. [Medline].

  35. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May. 39(5):1390-7. [Medline].

  36. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000 Dec. 119(6):1637-48. [Medline].

  37. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology. 1993 Apr. 17(4):564-76. [Medline].

  38. Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev. 2006. (4):CD003045. [Medline].

  39. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev. 2005. (4):CD002800. [Medline].

  40. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis- A randomized clinical trial. J Hepatol. Apr 2006. 44:784-90. [Medline].

  41. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003 Nov. 27(11):1765-72. [Medline].

  42. Rambaldi A, Jacob BP, Iaquinto G, et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases- a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. Nov 2005. 100:2583-2591.

  43. Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009 Aug. 137(2):541-8. [Medline].

  44. Bucci L, Garuti F, Camelli V, et al, for the Italian Liver Cancer (ITA.LI.CA) Group, Italian Liver Cancer ITA LI CA Group. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2015 Dec 14. [Medline].

  45. Jaruvongvanich V, Upala S, Sanguankeo A. Association between systemic inflammatory response syndrome and mortality in alcoholic hepatitis: A meta-analysis. Hepatology. 2015 Dec 8. [Medline].

  46. Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2015 Dec 7. [Medline].

Liver biopsy sample shows typical findings of perivenular polymorphonuclear infiltrate and ballooning degeneration of hepatocytes (hematoxylin and eosin [H&E] stain). Courtesy of H. Robert Lippman, MD.
Ethanol (ETOH) and cytokine production. CYP = cytochrome P; IL = interleukin; NF-κB = nuclear factor-kappa B; ROS = reactive oxygen species; TNF = tumor necrosis factor.
Mechanisms of cytokine injury. IL = interleukin ; NO = nitric oxide; O2- = superoxide anion; OH- = hydroxyl radical; PMN = polymorphonuclear lymphocyte; TNF = tumor necrosis factor.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.